http://www.biospace.comhttp://www.biospace.comTue, 16 Mar 2010 22:14:10 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2009http://www.biospace.com/news_story.aspx?StoryID=174038&full=1<p></p><p></p><p></p><p>INDIANAPOLIS and MELBOURNE, Australia, March 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company and Acrux announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON(TM)). The new drug application for AXIRON is currently under regulatory...Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174031&full=1BASEL, Switzerland, March 16, 2010 /PRNewswire/ -- 4-Antibody AG today announces a major long-term collaboration with Boehringer Ingelheim to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications. 4-Antibody will use its proprietary and unencumbered Hu-PAC(R) and Retrocyte Display(R) technologies for the discovery and development of fully...Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174041&full=1BBC News -- A receding hairline can be a good thing, according to US scientists, who say men who go bald by 30 appear to be less likely to develop prostate cancer.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174051&full=1The Wistar Institute -- PHILADELPHIA (March 15, 2010) A quest that began over a decade ago with a chance observation has reached a milestone: the identification of a gene that may regulate regeneration in mammals. The absence of this single gene, called p21, confers a healing potential in mice long thought to have been lost through evolution and reserved for creatures like flatworms, sponges, and...Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174022&full=1Reuters -- The addition of the Novartis (NOVN.VX) blood pressure medicine Tekturna to current standard drugs in patients who had a heart attack failed to help prevent changes in the heart's shape and worsening of its blood pumping ability, according to data from a study.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174026&full=1MedPage Today -- ATLANTA -- Atrial fibrillation is both a major stroke risk and a looming public health problem since the risk of afib increases with age, and the standard treatment, warfarin, is often a clinical management challenge. But a number of investigational therapies suggest that a post-warfarin era is beginning.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174030&full=1Newswise Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel a drug that prevents blood clots were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at...Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174043&full=1NEW YORK (Reuters Health) - People who take certain drugs for depression known as selective serotonin reuptake inhibitors (SSRIs) may have a higher-than-average risk of developing cataracts, a study from Canada hints.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174034&full=1LA Times -- Men treated for ED should routinely be checked for cardiovascular problems, experts say. For the first time, researchers have shown that erectile dysfunction is a strong predictor of the likelihood that men will die of heart disease.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174049&full=1Ottawa Health Research Institute -- Scientists from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa have identified a promising new approach for developing drugs to treat Spinal muscular atrophy (SMA), the leading inherited cause of death in infants and toddlers. Dr. Rashmi Kothary and his doctoral student Melissa Bowerman have found that an enzyme called RhoA is overly active...Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174134&full=1ScienceDaily (Mar. 16, 2010) Biologists at UC San Diego have discovered that a protein from a soil bacterium used to kill insects naturally on organic crops is a highly effective treatment for intestinal parasitic roundworms. These parasites, which include hookworms and whipworms, infect about two billion people in underdeveloped tropical regions and are cumulatively one of the leading causes of...Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174025&full=1MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton...Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174045&full=1BBC News -- Forget the collagen, for the perfect pout plump for a lip graft using muscle from your neck, according to US cosmetic surgeons.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174028&full=1Reuters -- AstraZeneca (AZN.L) expects double-digit growth in emerging markets, the new battleground for Big Pharma as sales in Western markets stall, but said on Tuesday it would be much more selective than some of its rivals.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174050&full=1EurekAlert! -- TAMPA, Fla. (March 16, 2010)Bone marrow stem cells suspended in X-ray-visible microbubbles dramatically improve the body's ability to build new blood vessels in the upper legproviding a potential future treatment for those with peripheral arterial disease or PAD, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174039&full=1Reuters -- Dynavax Technologies Corp (DVAX.O) said its auditors have expressed doubts on the company's ability to continue as a going concern as a result of the company's current financial position.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174044&full=1<p>SAN FRANCISCO, March 15 /PRNewswire-FirstCall/ -- Medivation, Inc. today provided a corporate update and reported its financial results for the year ended December 31, 2009.</p><p></p><p>"We are disappointed by the results of the Phase 3 CONNECTION trial in Alzheimer's patients, and it is our highest priority to work with our colleagues at Pfizer to further analyze the data and determine next steps...Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174054&full=1Reuters -- Ista Pharmaceuticals Inc (ISTA.O) made misleading claims about Xibrom eye solution in sales material, U.S. regulators said in a letter released on Tuesday.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174046&full=1WTNH -- Police are investigating an over-the-weekend drug heist at a Connecticut warehouse filled with prescription drugs. Investigators say it appears a group of people broke into the building and stole up to $75 million worth of prescription drugs.Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=174042&full=1VANCOUVER, BRITISH COLUMBIA--(Marketwire - 03/16/10) - Tekmira Pharmaceuticals Corporation (TSX:TKM - News), a leading developer of RNA interference (RNAi) therapeutics, announced today the initiation of a new research collaboration with Pfizer (NYSE:PFE - News).</p><p>Tekmira and Pfizer will collaborate on evaluating Tekmira's stable nucleic acid-lipid particle (SNALP) technology to deliver small...Tue, 16 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173862&full=1SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., March 15, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN - News), Eli Lilly and Company (NYSE:LLY - News) and Alkermes, Inc. (Nasdaq:ALKS - News) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON (exenatide for extended-release...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173858&full=1Reuters -- The Novartis (NOVN.VX) diabetes drug Starlix failed to reduce progression to the disease or cut down on serious heart problems in patients at high risk for both diabetes and heart disease, according to a large study released on Sunday.Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173876&full=1MedPage Today -- Combining sertraline (Zoloft) and the opioid antagonist naltrexone better than either drug alone or placebo in keeping depressed alcoholics sober, researchers said.Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173873&full=1VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq:MNKD - News) today announced that it has received a Complete Response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes mellitus for the control of hyperglycemia...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173875&full=1MedPage Today -- ATLANTA -- Two years after beginning lipid-lowering therapy with an investigative treatment combining rosuvastatin (Crestor) with fenofibric acid (Trilipix), patients maintained an improved lipid profile without new adverse effects, researchers said. Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173877&full=1ATLANTA (Reuters) - Adding a triglyceride-lowering drug to cholesterol-fighting statins provided no additional protection from heart attack, stroke and death from heart disease in patients with Type 2 diabetes, according to data from a large study.Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173884&full=1SCOTTSDALE, Ariz. - March 11, 2010 - Many women live with breast cancer that does not respond to standard medical treatment, a condition that researchers at the Virginia G. Piper Cancer Center at Scottsdale Healthcare want to change by aggressively targeting specific genes.Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173872&full=1SOUTH SAN FRANCISCO, Calif., March 15 /PRNewswire/ -- NGM Biopharmaceuticals today announced it has closed the first tranche of a $51 million Series B round of financing. The Series B round included The Column Group, Tichenor Ventures, LLC, Prospect Venture Partners, Rho Ventures and other new and Series A investors. With this financing, NGM also announced the appointment of McHenry (Mac) T. Tichenor...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173883&full=1ScienceDaily (Mar. 14, 2010) New findings that shed light on how genetic damage to muscle cell proteins can lead to the development of the rare muscle-wasting disease, nemaline myopathy, are reported March 15 in the Biochemical Journal.Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173870&full=1MELVILLE, N.Y., Mar 15, 2010 (BUSINESS WIRE) -- --Board Recommends Stockholders Not Tender Shares at $52.00 per Share</p><p>--Company, With Assistance of Financial Advisors, to Contact Third Parties</p><p>OSI Pharmaceuticals, Inc. /quotes/comstock/15*!osip/quotes/nls/osip (OSIP 58.34, 0.66, 1.14%) today announced that its Board of Directors, after careful review and consideration with the...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173866&full=1GHENT, BELGIUM--(Marketwire - 03/15/10) - This announcement is an advertisement and not a prospectus. Investors should not subscribe for or purchase any securities referred to in this announcement except on the basis of information in the prospectus published by Ablynx NV (the "Company") on 26 February 2010 (which is supplemented by an addendum approved by the CBFA on 7 March 2010) in connection with...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173865&full=1BOSTON, March 15 /PRNewswire/ -- Rhythm Pharmaceuticals (Rhythm), a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that it has completed the first close on its Series A equity financing of $21 million. The financing was led by MPM Capital (MPM) and New Enterprise Associates (NEA). The funds will be used to develop products licensed from Ipsen (Euronext...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173869&full=1BRIDGEWATER, N.J. & PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis U.S. and Bristol-Myers Squibb Company (NYSE: BMY - News) today announced revisions to the U.S. prescribing information for PLAVIX (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173864&full=1Reuters -- Inspire Pharmaceuticals Inc (ISPH.O) said its experimental eye drug, Azasite, failed to meet the main goals of two mid-stage trials.Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173861&full=1ROCHESTER, NY--(Marketwire - 03/15/10) - Bausch Lomb has named Fred Hassan as chairman of the Board of Directors and has named Brent Saunders as chief executive officer and appointed him to the Board of Directors, effective immediately.</p><p>Current Chairman and CEO Gerald M. Ostrov is retiring, and will serve as a consultant to the new leaders.</p><p>Mr. Hassan is one of the leading figures...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173859&full=1ATLANTA--(BUSINESS WIRE)--Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a once-daily dose of oral betrixaban, given to patients with non-valvular atrial fibrillation or atrial flutter and at least one risk factor for stroke, reduced the incidence...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173874&full=1Reuters -- Mylan (MYL.O) has withdrawn its application to market a generic version of Sanofi-Aventis's (SASY.PA) cancer drug in Europe, after adverse feedback from regulators.Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173816&full=1Reuters -- MiddleBrook Pharmaceuticals Inc (MBRK.O) said its auditors have expressed doubts on the company's ability to continue as a going concern and that it was evaluating strategic options, which may include selling itself.Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173881&full=1ScienceDaily (Mar. 14, 2010) The promise of stem cells lies in their unique ability to differentiate into a multitude of different types of cells. But in order to determine how to use stem cells for new therapeutics, scientists and engineers need to answer a fundamental question: if a stem cell changes to look like a certain type of cell, how do we know if it will behave like a certain type of cell...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173882&full=1Newswise A potent new inhibitor of HIV, derived from bananas, may open the door to new treatments to prevent sexual transmission of HIV, according to a University of Michigan Medical School study published this week. Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173871&full=1Researchers at the Genome Institute of Singapore (GIS), Associate Director for Infectious Diseases Dr Martin Hibberd and Assoc Prof Mark Seielstad; and the Karolinska Institutet (KI) in Stockholm, Sweden, Assoc Prof Leif Trkvist, Assoc Professor Mauro DAmato and Prof Sven Pettersson, have collaborated with research teams from the USA, the Netherlands, and Italy to identify genes increasing the likelihood...Mon, 15 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173734&full=1NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC). An independent Data Safety Monitoring...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173733&full=1NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that two Phase 3 studies of Sutent (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173728&full=1SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute (NCI) investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173736&full=1ScienceDaily (Mar. 12, 2010) Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173737&full=1ScienceDaily (Mar. 11, 2010) A clinical research trial of a new treatment to restore brain cells damaged by stroke has passed an important safety stage, according to the UC Irvine neurologist who led the effort.Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173738&full=1EurekAlert! -- TUSCALOOSA, Ala. Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms. Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173746&full=1ScienceDaily (Mar. 11, 2010) Scientists at the University of Essex have a greater understanding of how our genes are controlled following a major research project.Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173723&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173729&full=1PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Ipsen (Paris:IPN - News) (Euronext: FR0010259150; IPN), a global biotechnology specialty care group, and Rhythm Pharmaceuticals (Rhythm), a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsens proprietary peptide therapeutics targeting obesity, metabolic...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173731&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO - News), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at $9.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by AVEO...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173735&full=1University of Iowa -- Current drugs used to treat heart failure and arrhythmias (irregular heartbeat) have limited effectiveness and have side effects. New basic science findings from a University of Iowa study suggest a way that treatments could potentially be refined so that they work better and target only key heart-related mechanisms.Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173739&full=1MORRISTOWN, N.J., March 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI - News), today announced the U.S. Food and Drug Administration (FDA) approval of TRELSTAR 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR, a proven, simple and effective palliative treatment of advanced prostate cancer. With an anticipated May launch, TRELSTAR...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173765&full=1<p> TAIPEI, Taiwan, March 12 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability. Nemonoxacin is a novel non-fluorinated quinolone that has a broad spectrum of activity against gram-positive and...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173828&full=1BRIDGEWATER, N.J. & PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis U.S. and Bristol-Myers Squibb Company (NYSE: BMY) today announced revisions to the U.S. prescribing information for PLAVIX (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active metabolite...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173724&full=1TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - News) today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173743&full=1NEW YORK (Reuters Health) - Getting a bit more calcium in your diet could help you live longer, new research suggests.Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173818&full=1SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that GlaxoSmithKline (NYSE: GSK) was granted marketing authorization from the European Commission (EC) for Revolade (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). Eltrombopag is...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173745&full=1EurekAlert! -- Sexual problems are frequent after operations for carcinoma of the rectum. Christian Schmidt et al. describe the consequences for quality of life in the current issue of Deutsches rzteblatt International (Dtsch Arztebl Int 2010; 107[8]: 123-30).Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173742&full=1Reuters -- Privately held Azur Pharma Limited entered into a definitive agreement with Elan Pharmaceuticals Inc, a unit of Elan Corp (ELN.N), to buy its painkiller Prialt.Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173730&full=1WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ -- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.</p><p>The new outpatient dosing option provides...Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173726&full=1Reuters -- Arena Pharmaceuticals Inc expects to launch sales of its weight loss drug -- alone or with a partner -- within 12 weeks of U.S. regulatory approval, according to the company.Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173741&full=1LONDON (Reuters) - One of the world's largest studies of the contraceptive pill has found that women who have taken it can expect longer lives and are less likely to die from any cause, including cancer and heart disease.Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173826&full=1Orthosupersite -- NEW ORLEANS One of the first prospective, randomized studies to evaluate the effect of platelet-rich fibrin matrix in arthroscopic rotator cuff repair shows that the product has no significant impact on clinical results and perioperative pain control. Fri, 12 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173575&full=1The Sun News -- AstraZeneca PLC announced a supply partnership with India's Torrent Pharmaceuticals on Thursday, its first such link with a generic drugmaker as it seeks to boost its presence in emerging markets and counter patent losses on blockbuster medicines.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173569&full=1WASHINGTON (Reuters) - Recent new powers have helped the U.S. Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA officials said on Wednesday.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173554&full=1SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that Charles Homcy, M.D., president and chief executive officer, will retire from his current position and assume the role of co-chairman of the board of directors, effective May 1, 2010. Dr. Homcy has served as president and CEO since 2003, when he co-founded the company. Chief Operating Officer William...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173581&full=1ScienceDaily (Mar. 11, 2010) A Perspective piece in the New England Journal of Medicine calls for change in the way researchers and pharmaceutical companies collect and report adverse symptom information in clinical trials submitted to the Food and Drug Administration (FDA), and how the FDA represents this information on drug labels.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173586&full=1Crains Manchester Business -- More than 200 Manchester-based jobs are under threat at AstraZeneca after the pharmaceutical giant said previously announced plans to outsource some back office functions will affect its office in Chorlton-cum-Hardy.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173561&full=1MedPage Today -- The antiparasitic drug ivermectin (Stromectol) is more effective than malathion lotion for treating infections of drug-resistant lice, a new industry-sponsored study found.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173585&full=1DNA -- In the late nineties, when big pharmaceutical companies starting feeling the burden of over-sized research units in the face of a dwindling pipeline of molecules, they started looking at ways to source manufacturing at lower costs and to farm out semi-skilled chemistry work to Indian companies.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173566&full=1WASHINGTON (Reuters) - Two studies published on Wednesday show it is possible to sequence the entire gene maps of families with inherited diseases and pinpoint the offending bit of DNA.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173574&full=1ScienceDaily (Mar. 11, 2010) People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar. 11, issue of the New England Journal of Medicine, Johns Hopkins and Swedish researchers say an experimental drug called eprotirome lowered...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173565&full=1Reuters -- U.S. regulators said on Wednesday they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc's (MRK.N) Fosamax and certain thigh bone fractures.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173579&full=1ScienceDaily (Mar. 10, 2010) According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), older men with high levels of the hormone IGF-I (insulin-like growth factor 1) are at increased risk of cancer death, independent of age, lifestyle and cancer history.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173560&full=1FORT LEE, N.J.--(BUSINESS WIRE)--Neurologix, Inc. (OTCBB:NRGX - News), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that Clark A. Johnson, the Vice Chairman of Neurologix (the Company), has been appointed as the Companys President and Chief Executive Officer to replace John E. Mordock, who resigned.</p><p...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173553&full=1LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX - News) today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate). All patients enrolled in the trial used Gleevec for...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173593&full=1<p>NAPA, Calif., March 10 /PRNewswire-FirstCall/ -- Senetek PLC today announced the closing of a Security Purchase Agreement, a Note and a Warrant Purchase Agreement DMRJ Group, LLC on March 4, 2010. DMRJ Group, LLC is a Delaware limited liability company affiliated with Platinum Partners Value Arbitrage Fund L.P., an accredited institutional investor with its investment manager headquartered in New...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173576&full=1Deakin University -- A newly discovered ability for people to taste fat could hold the key to reducing obesity, Deakin University health researchers believe.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173577&full=1MarketWatch -- Basilea Pharmaceutica AG, the Basel drugmaker, said on Thursday that a Johnson & Johnson subsidiary asked the European Committee For Medicinal Products for Human Use to re-examine its rejection of ceftobiprole to treat complicated skin and soft-tissue infections.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173572&full=1New Scientist -- DRUGS that keep prostate cancer at bay often stop working after a few years. That now appears to be because they prompt the growth of the very tumour cells they are meant to kill. It's not all bad news, though: blocking this growth pathway could buy time for men with drug-resistant tumours.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173570&full=1SOUTH SAN FRANCISCO, Calif., March 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News) (Stockholm:OXGN - News), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173580&full=1Alibaba -- There are plans to build the largest global contract bio-pharmaceutical base in Asia in Beijing, with a total investment of about $120 million, Xinhua website reported on March 9.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173564&full=1Newswise Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173571&full=1ATLANTA, March 11 /PRNewswire/ -- UCB today announced that the antiepileptic drug (AED) Vimpat (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.</p><p>This study was one of three that supported the approval of Vimpat by the U.S. Food and Drug Administration...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173587&full=1Pittsburgh Business Times -- An ambitious plan to build a vaccine factory in the Pittsburgh area is gaining momentum with the announcement Thursday of three new partners in the University of Pittsburgh Medical Center project.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173578&full=1Bloomberg -- Merck & Co.s Stromectol tablet worked better than lotion at clearing up hard-to-treat head lice, a study found, as the infestations become increasingly resistant to current medicines. Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173377&full=1Provides Promising Biologic Intended to Treat Multiple Sclerosis and Compounds that Complement Abbott's Existing Diverse Oncology Program</p><p>ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT - News) and Facet Biotech Corporation (Nasdaq:FACT - News) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173410&full=1Dow Jones -- After years of anticipation, a long-acting version of diabetes drug Byetta, sold by Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY), faces a crucial Food and Drug Administration approval decision this week.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173398&full=1Reuters -- Novartis has taken an exclusive option to develop Transgene's (TRNG.PA) cancer vaccine TG4010, but the deal fell short of investors' hopes, pulling the shares in the French biotechnology company down 12 percent.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173407&full=1ScienceDaily (Mar. 9, 2010) A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173378&full=1BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq:ITMN - News) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. </p><p>IPF is a rare and...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173195&full=1SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq:EXEL) today announced a restructuring as a consequence of its continued strategy to focus resources on the development of its key late-stage compounds. As its first priority, the company will aggressively advance XL184, XL147 and XL765, each of which is the subject of a large clinical development program. Additionally, Exelixis retains...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173406&full=1Henry Ford Hospital -- DETROIT - In the first study of its kind in the United States, Henry Ford Hospital showed that skin transplant surgery is safe and effective for treating vitiligo.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173403&full=1Reuters -- Cytokinetics Inc (CYTK.O) said its experimental drug for the treatment of a neurodegenerative disease received orphan drug status from U.S. health regulators, sending its shares up 5 percent in premarket trade.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173417&full=1UCSD -- Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algaerapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173418&full=1Examiner -- Fosamax, a popular osteoporosis medication for which nearly 40 million prescriptions have been written, may be putting some at risk for spontaneous femur fractures. Fosamax is part of a group of drugs called bisphosphonates designed to make bones stronger.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173393&full=1MORRISTOWN, N.J., March 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI - News), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets. Under...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173408&full=1University of Missouri -- COLUMBIA, Mo. According to the Journal of Sexual Medicine, people who engage in regular sexual activity gain several health benefits, such as longer lives, healthier hearts, lower blood pressure, and lower risk of breast cancer. However, approximately 33 percent of women may not receive these benefits due to low sexual desire. Also, the marriages of women with low sexual...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173409&full=1AP -- The chief executive of drugmaker Bristol-Myers Squibb Co., James Cornelius, received a 2009 compensation package valued by The Associated Press at $17 million, down 22 percent from 2008, due to the much lower value of his stock awards.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173395&full=1PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY - News) today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies exclusive global agreement to develop and commercialize Hematide, Affymaxs investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173392&full=1Newswise An analysis by researchers at the Keck School of Medicine of the University of Southern California (USC) has found that only 32 percent of medication studies published in top medical journals compare the effectiveness of existing treatments. These studies, known as comparative effectiveness studies, help doctors know which therapies work best and under what circumstances they are most effective...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173413&full=1Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today provides an update to shareholders on developments in relation to the proposed sale or merger of the Company.</p><p>Neuropharm has been in discussions with a number of parties since it entered an offer period on 3 November 2009 and announced that it was pursuing a proposed sale or...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173394&full=1PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS - News), a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn Skin and Wound...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173404&full=1Emory University -- The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173400&full=1IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN - News) today announced that the United States Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity.</p><p>Spasticity is a debilitating condition impacting approximately 1 million Americans1, many of...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173405&full=1EurekAlert! -- Tears in the shoulder's rotator cuff, a common sports injury, are painful and restricting. Surgery to repair the damage is successful for pain management, but in many patients it does not result in full recovery of function due to poor healing. New research shows an approved therapy for osteoporosis, Forteo, may speed healing and improve patient outcomes. The preliminary study from Hospital...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173399&full=1ScienceDaily (Mar. 10, 2010) Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173402&full=1Melbourne, 10 March 2010. The independent business analyst forecasts that the antidiabetics market will be worth $37 billion by 2018 up from $20 billion in 2008. This rapid market expansion presents significant opportunities for pharmaceutical companies who are able to develop new therapies to address the unmet clinical needs in type 2 diabetes. In contrast, Datamonitor expects opportunities in the...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173219&full=1London, UK, 9 March 2010: The Board of Ark Therapeutics Group plc ("Ark" or "the Company") today announces an update relating to the Marketing Authorisation Application ("MAA") for its brain cancer treatment, Cerepro. Following a presentation to the EMEA's Scientific Advisory Group on Oncology ("SAG-O") as part of the re-examination procedure, the SAG-O did not consider that the current study provides...Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173272&full=1Science Insider -- With the struggling economy putting a squeeze on research funding in the United Kingdom, a government-appointed advisory panel called the Council for Science and Technology today released a report about the future of Britain's scientific enterprise. Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173212&full=1BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc. announced that NASDAQ has today halted trading of InterMune's common stock. The Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the U.S. Food and Drug Administration (FDA) meets today to review and discuss the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis...Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173242&full=1Howard Hughes -- New World hemorrhagic fevers are emerging infectious diseases found in South America that can cause terrible, Ebola-like symptoms. Current treatments are expensive and only partially effective.Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173237&full=1BusinessWeek -- Electrocardiogram screening to check for heart problems in hyperactive children before prescribing stimulant medications may help identify those at risk, but is only borderline cost-effective compared to the current practice of taking a patient history and doing a physical examination, a new study shows.Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173230&full=1LA Times -- Women who abstained put on more pounds than those who had a drink or two per day. But researchers warn against an alcohol diet.Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173234&full=1LONDON (Reuters) - Vitamin D is vital in activating human defences and low levels suffered by around half the world's population may mean their immune systems' killer T cells are poor at fighting infection, scientists said on Sunday.Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173235&full=1WASHINGTON (AP) -- The virus that causes AIDS can hide in the bone marrow, avoiding drugs and later awakening to cause illness, according to new research that could point the way toward better treatments for the disease.Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173257&full=1PASADENA, Calif., March 9 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today announced that its Board of Directors has determined, after consideration of potential strategic alternatives, that it is in the best interests of the Company and its stockholders to liquidate the Company's assets and to dissolve the Company. In connection with the liquidation, the Company intends...Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173313&full=1Toulouse, France, March 9, 2010 - BT Pharma, a biopharmaceutical company developing innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces today that it has raised EUR 13.1 million in additional funding and changed its name to Genticel. AGF Private Equity led the round, which brought in three new investors, IRDI (Institut Rgional de Dveloppement Industriel...Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173218&full=1Bloomberg -- OSI Pharmaceuticals Inc.s status as one of the few U.S. biotechnology companies with income from an approved cancer drug likely will drive up the price Tokyo-based Astellas Pharma Inc. must pay to acquire it.Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173217&full=1IRVINE, Calif., March 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq:ISTA - News), today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA has granted XiDay a standard review time of ten months, assigning ISTA a Prescription Drug...Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173214&full=1PARIS & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK - News): Sanofi-aventis (EURONEXT: SAN) (NYSE: SNY - News) and Merck & Co., Inc. (NYSE: MRK - News) announced today that sanofi-aventis has exercised its option to combine Merial with Intervet/Schering-Plough, Mercks Animal Health business, to create a global leader in Animal Health.</p><p>The new joint venture will...Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173213&full=1Reuters -- Matrixx Initiatives Inc said U.S. health regulators declined to withdraw the warning letter on the company's nasal versions of Zicam cold remedy.Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173239&full=1ScienceDaily (Mar. 9, 2010) A new method of growing arteries could lead to a "biological bypass" -- or a non-invasive way to treat coronary artery disease, Yale School of Medicine researchers report with their colleagues in the April issue of Journal of Clinical Investigation.Tue, 09 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173236&full=1SIFY -- Warfarin users appear more likely to develop brain haemorrhage following stroke treatment with the anticoagulant, a new study has found.Tue, 09 Mar 2010 12:00:00 AM GMT